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RESEARCH Open Access
Effects of low- and high-intensity physical
exercise on physical and cognitive function
in older persons with dementia: a
randomized controlled trial
L. M. J. Sanders1*, T. Hortobágyi1, E. G. A. Karssemeijer2, E. A. Van der Zee3, E. J. A. Scherder4 and
M. J. G. van Heuvelen1
Abstract
Background: Potential moderators such as exercise intensity or apolipoprotein-E4 (ApoE4) carriership may determine
the magnitude of exercise effects on physical and cognitive functions in patients with dementia (PwD). We determined
the effects of a 24-week aerobic and strength training program with a low- and high-intensity phase on physical and
cognitive function.
Methods: In an assessor-blinded randomized trial, 91 PwD (all-cause dementia, recruited from daycare and residential
care facilities, age 82.3 ± 7.0 years, 59 women, Mini-Mental State Examination 20.2 ± 4.4) were allocated to the exercise
or control group. In the exercise group, PwD participated in a walking and lower limb strength training program with
12 weeks low- and 12 weeks high-intensity training offered three times/week. Attention-matched control participants
performed flexibility exercises and recreational activities. We assessed adherence, compliance, and exercise intensity for
each session. We assessed physical (endurance, gait speed, mobility, balance, leg strength) and cognitive (verbal
memory, visual memory, executive function, inhibitory control, psychomotor speed) functions with performance-based
tests at baseline and after 6, 12, 18, 24, and 36 weeks (follow-up). ApoE4 carriership was determined post-intervention.
Results: Sixty-nine PwD were analyzed. Their mean attendance was ~ 60% during the study period. There were no
significant effects of the exercise vs. control intervention on endurance, mobility, balance, and leg strength in favor of
the exercise group (Cohen’s d = 0.13–0.18). Gait speed significantly improved with ~ 0.05m/s after the high-intensity
phase for exercise participants (Cohen’s d = 0.41) but declined at follow-up. There were no significant effects of the
exercise vs. control intervention on any of the cognitive measures (Cohen’s d ~ − 0.04). ApoE4 carriership did not
significantly moderate exercise effects on physical or cognitive function.
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Conclusions: Exercise was superior to control activities for gait speed in our sample of PwD. However, the training effect
provided no protection for mobility loss after detraining (follow-up). There were no beneficial effects of the exercise vs.
control group on cognitive function. Exercise intensity moderated the effects of exercise on gait speed. ApoE4 carriership
moderated the effect of exercise on global cognition only (trend level).
Trial registration: Netherlands Trial Register, NTR5035. Registered on 2 March 2015.
Keywords: Dementia, Cognitive decline, Physical exercise, Exercise intensity, Dose-response relationship, ApoE4
Background
The number of older persons with dementia (PwD) is
growing from 50 million worldwide in 2017 to 80 million
in 2030 [1]. Dementia is characterized by progressive neu-
rodegeneration and severe functional losses. The clinical
relevance of pharmacological treatments remains uncer-
tain, and the risk of adverse reactions is high [2]. Exercise
may be a treatment alternative to drugs to slow functional
declines in dementia. In healthy older adults, both aerobic
and strength exercises are associated with improvements
in cognitive functions such as executive function, inhibi-
tory control and episodic memory [3–5], and physical
functions, i.e., muscle strength, balance, functional reach,
mobility, and endurance [4, 6–9]. Regrettably, the effects
of exercise on these cognitive and physical functions in
PwD have been inconsistent [5, 10–14]. In PwD, com-
bined aerobic and strength exercise appears to be more ef-
fective for cognitive and physical benefits than aerobic
training only [11].
Neuroprotective effects of exercise may be mediated
by exercise-induced increases in brain-derived neuro-
trophic factor (BDNF), insulin-like growth factor-type I
(IGF-1), vascular endothelial growth factor (VEGF), and
homocysteine [15–23] thereby promoting structural and
connectivity changes in the brain areas important for
memory and executive function, e.g., frontal and tem-
poral lobes and hippocampus [24–27].
There is no conclusive evidence for exercise as a treat-
ment modality for PwD. Identifying the variables that
moderate the relationship between cognition and physical
function is needed to optimize exercise programs [28]. A
few potential moderators have been identified. For
example, the presence of the apolipoprotein-E4 (ApoE4)
allele, a risk factor for Alzheimer’s disease (AD) [29], may
mediate the magnitude of exercise effects. Accumulation
of neuronal and physiological damage in ApoE4 carriers
may negate the beneficial effects of physical activity [30,
31]. Conversely, ApoE4 carriers may be more responsive
to exercise [32], perhaps because lower functional levels at
baseline [33–36] leave more room for improvement. In
addition to ApoE4 carriership, exercise intensity may de-
termine the magnitude of exercise effects. Exercise-
induced changes in the aforementioned neurobiological
factors may be dose-dependent, as evidenced by studies in
rodents [37, 38] and humans [18, 39, 40]. Furthermore,
exercising at moderate-to-vigorous intensities is recom-
mended over lighter intensities for cardiovascular, muscu-
lar, and neuromotor benefits in healthy young and old
adults [41]. Whether this is true also for cognitive func-
tions is undetermined [5].
In the current sample of PwD, we aimed to determine
(1) the feasibility of low- vs. high-intensity combined aer-
obic and strength training, (2) the dose-response effects of
low- and high-intensity combined aerobic and strength
exercise on physical and cognitive functions, (3) if high-
vs. low-intensity exercise has differential effects on phys-
ical and cognitive functions, and (4) whether ApoE4 mod-
erates the effects of exercise. We hypothesized that (1) a
6-month combined aerobic and strength training program
with a low- vs. high-intensity phase would be feasible in
our sample, (2) the exercise program would reduce the
rate of decline in physical and cognitive function, (3) the
beneficial effects would be greater after high- vs. low-
intensity exercise, and (4) that ApoE4 carriership would




We assessed the effects of a 6-month combined aerobic
and strength training program with a low (LI, week 1–
12) and high (HI, week 13–24) intensity phase compared
to a control program of matched attention in a random-
ized controlled study design. We performed blinded as-
sessments of cognitive and physical functions at T0, T12
(after 12 weeks), and T24 (after 24 weeks). Brief (blinded)
assessments of a selection of cognitive and physical func-
tions were performed at T6 (after 6 weeks), T18 (after
18 weeks), and T36 (follow-up after 36 weeks). After 24
weeks, a saliva sample was taken to determine ApoE4
carriership. We included patients with mild-to-moderate
dementia who attended daycare or resided in residential
care facilities with open front door policies. A power
analysis on our design using a small-to-medium effect
size (ES), alpha = 5%, power = 80%, and expected drop-
out of 25% resulted in a minimal sample size of 59 par-
ticipants per group. The ES for this power analysis was
based on the eight most sensitive tests in a previous
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study by Bossers et al. [11] (ES = 0.21–0.31) with correla-
tions between pretest and post-test of r = 0.65–0.85.
Participants
Between September 2015 and October 2017, participants
were recruited from 13 health care locations that pro-
vided daycare or residential care for PwD. Health care
staff selected potential participants based on the instruc-
tions from the researchers. These instructions were that
potential participants had to be able to walk with or
without an assistive walking device had to have sufficient
ability to follow instructions and had to be interested in
participating in a scientific study. With oral consent
from participants and their caregivers, health care staff
provided the names and contact information of the se-
lected potential participants. The researchers provided
these potential participants and their caregivers with fur-
ther oral and written information. After oral and written
informed consent was obtained from participants and
their caregivers, participants were screened further for
eligibility by a trained research assistant. Participants
were then included if they met the following criteria: a
dementia diagnosis determined by a primary care phys-
ician or geriatrician (the Dutch College of General Prac-
titioners advises to use the Diagnostic and Statistical
Manual of Mental Disorders fourth edition (DSM-IV)
for the diagnosis of dementia [42]), age ≥ 65 years, a
physician-determined all-cause dementia diagnosis, able
to complete the Timed Up & Go (TUG [43]) with or
without an assistive device, and a Mini-Mental State
Examination (MMSE [44]) score > 10 corresponding to
mild-to-moderate dementia. Participants were excluded
if they met one of the following criteria: wheelchair-
bound; presence of severe cardiovascular problems that
limit physical activity or brain trauma, epilepsy, progres-
sive or terminal disease, and/or depression; history of al-
coholism and/or Korsakoff’s syndrome; severe visual or
auditory problems; non-fluent in the Dutch language;
and mental incompetence without a legal guardian.
Procedures
The Ethical Committee of the University Medical Center
Groningen approved the study (METc 2014/523). The
Dutch Trial Registration number is NTR5035. We ob-
tained oral and written informed consent from partici-
pants and their caregivers. The study was conducted in
accordance with the Declaration of Helsinki (64th
amendment).
Participants were randomly assigned to the combined
aerobic and strength training intervention (“exercise”) or
control intervention (“control”) with an allocation ratio of
1:1. We stratified participants according to MMSE, gen-
der, and health care location, so that the number of exer-
cise vs. control participants was approximately equally
distributed according to MMSE score, gender, and health
care location.
The program duration was 24 weeks for both the
exercise and control interventions. Participants in the
exercise and control interventions were offered 72 in-
dividualized sessions (3/week for 24 weeks—for the
exercise group, this amounted to 36 walking sessions
and 36 strength exercise sessions) of 30 min each.
This combination of combined walking and strength
exercise, 3 sessions/week for 24 weeks, previously
showed the highest efficacy on physical and cognitive
outcomes in PwD [11, 45]. Each session was super-
vised on a one-on-one basis by a trained research as-
sistant who was assigned to the participant. Each
research assistant kept a log of each session. The log
was used to continuously record the heart rate and
rate of perceived exertion (RPE) during the session,
activity specifics, participant satisfaction, and note-
worthy details. The research assistants used these var-
iables to establish the targeted exercise intensity. In
addition, the research assistants evaluated the quality
of every strength exercise according to the protocol
(such as exercise execution, posture, leg straightening)
on a scale of 1 (insufficient) to 4 (good).
Exercise intervention
Aerobic sessions
The aerobic sessions consisted of outdoor walking. If the
weather did not allow for outdoor walking or the participant
rejected outdoor walking, walking was performed indoors.
Subjects in the exercise intervention exercised at LI for the
first 12weeks and at HI for the subsequent 12weeks. The
target intensity of sessions was determined in correspond-
ence with the American College of Sports Medicine (ACSM
[46]) guidelines for “low” and “moderate-to-high” intensity
exercise. The intensity of the aerobic sessions was monitored
objectively every 5 min using a MIO Link Continuous Heart
Rate Wrist Band. Subsequently, training intensity was deter-
mined objectively using the percentage of maximum heart
rate (%HRmax, with HRmax = 208− (0.7 × age)) and subject-
ively with observer-determined RPE using a Borg scale. The
Borg scale ranges from 6 to 20, with 6 corresponding to min-
imal intensity and 20 to maximal intensity. In the LI phase,
the target RPE was 9–11 and target HR was 57–63%HRmax.
In the HI phase, participants performed interval training with
alternating 4-min peak performance at RPE 15–16 and 83–
89%HRmax and 3-min active rest at RPE 13–14 and 71–
77%HRmax. Although we do not deem the observer-rated
RPE to be superior to HR measures when determining exer-
cise intensity, we instructed the research assistants to rely on
the observer-rated RPE in case of discrepancies between RPE
and heart rate which could be due to beta blockers. Walking
intensity could be increased or decreased by adapting walk-
ing speed and the number of passive or active rests.
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Strength sessions
Lower limb strength exercises can help enhance walking
ability and produce a stronger neuromotor stimulus
[11]. Four lower limb exercises were performed during
the strength sessions in a fixed sequence: (1) knee exten-
sion while sitting, (2) plantar flexion (toe standing), (3)
hip abduction (side leg lifts), and (4) hip extension (back
leg lifts). A chair was used for support. Per session, the
muscle contractions were either isometric, concentric, or
eccentric (so that 12 isometric, 12 concentric, and 12 ec-
centric contraction sessions were offered throughout the
exercise intervention). We used only the target RPE to
determine the intensity because no significant increases
in heart rate were expected.
The intensity of the strength sessions was determined
subjectively with the observer-determined RPE. In the LI
phase, the target RPE was 9–11. In the HI phase, the
RPE was 13–16. Exercise intensity could be increased or
decreased by adapting the number of sets and repetitions
(Additional file 1: Appendix 1). Ankle weights were
added in the HI phase per 0.5 kg for all exercises except
toe stands. The added weight was increased equally for
all exercises (except toe stands).
Control intervention
The control intervention consisted of flexibility exercises
and recreational activities (matched attention). The flexi-
bility exercises included upper and lower body exercises
such as neck or shoulder rotation and stretching knee
flexors and extensors. No weights were used. Addition-
ally, recreational activities such as board games or social




We collected information on dementia diagnosis [42],
comorbidities (Functional Comorbidity Index-18 (FCI-
18 [47]), and medication use from medical files kept by
each participants’ general practitioner. Anticholinergic
and sedative drug burden was represented by the Drug
Burden Index (DBI [48]).
ApoE4 status
We used sterile buccal swabs to take saliva samples for
APOE genotyping. Buccal samples were analyzed using
the real-time polymerase chain reaction (PCR) method
[49]. This resulted in six different potential APOE geno-
types (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, e4/e4).
Physical function
We used five physical function tests that are deemed
suitable for PwD [50]. Additional file 1: Appendix 2a de-
scribes these tests in more detail. The 6-minute walk test
(6MWT) [51] measures endurance. The Short Physical
Performance Battery (SPPB) [52] assesses lower body
strength and functional mobility. We measured habitual
gait speed with the 6-meter walking speed test (6MWS).
We used the FICSIT-4 [53] as a static balance measure.
We assessed lower body muscle strength with the Quad-
riso table (see Additional file 1: Appendix 2a for details).
The Quadriso table is a lower body force-measuring de-
vice based on the Quadrisotester of Verkerke et al. [54].
The TUG measures functional mobility.
All tests were performed at T0, T12, and T24. 6MWS
and leg strength were assessed at T6, T18, and T36 as well.
Cognitive function
We assessed cognitive function with neuropsychological
tests that were previously used in PwD [50]. Add-
itional file 1: Appendix 2b describes these tests. Global
cognition was assessed with the MMSE. We measured the
psychomotor speed with the Trail Making Test A
(TMTA) [55]. The Digit Span Forward (DSFW) and Back-
ward (DSBW) [56] measure verbal memory span and ver-
bal working memory, respectively. The Visual Memory
Span Forward and Backward (VMSFW and VMSBW) [56]
are measures of respectively visual memory span and
visual working memory. The STROOP test [57] is used to
assess basic attentional processing and inhibitory control.
We used the phonemic fluency test (Fluency) [58] as an
executive function measure.
All tests were performed at T0, T12, and T24. The
STROOP test was also performed at T6, T18, and T36.
Statistical analyses
We used SPSS 25.0 (IBM: Armonk, NY) to compute
means and standard deviations and to analyze the data
with a two-tailed significance set at p < 0.05. Scores on
the TMTA, STROOP interference, TUG, and 6MWS
were right-skewed and therefore natural-log trans-
formed. We accounted for missing values on cognitive
and physical variables at T0, T6, T12, T18, T24, and
T36 with multiple imputation (9.2% of the cognitive var-
iables missing (3.2% T0, 5.3% T6, 10.0% T12, 6.8% T18,
12.9% T24, and 20.3% T36) and 9.2% of the physical var-
iables missing (2.4% T0, 13.0% T6, 8.9% T12, 10.1% T18,
11.1% T24, and 19.6% T36)); automatic model setting;
40 imputations; and 100 iterations (done separately for
physical vs. cognitive variables and exercise vs. control
group). Reasons for missing values were illness, refusal
of assessment, or being otherwise (temporarily) unavail-
able. We performed adapted intention-to-treat analyses
by selecting all individuals who completed ≥ 5 assess-
ments independent of attendance (N = 69, 39 exercise
group). Group differences for physical and cognitive out-
comes were assessed with analyses of covariance
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(ANCOVA) with continuous baseline variables as
covariates.
To determine the magnitude of exercise effects, we





− postcont  precontð Þffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2pre; exp  nexp þ s2pre;cont  ncont
nexp þ ncont þ




where “post” represents T12 or T24 measurements,
“exp” represents exercise, and “cont” represents the con-
trol group. Values of d = 0.20, d = 0.50, and d = 0.80 indi-
cate small, medium, and large effect sizes [59],
respectively; 95% confidence intervals (CIs) for d were













We considered an effect to be a dose-response effect
with respect to intensity if the change from baseline T24
(LI+HI phase) was higher or equal (as we expected that
potential beneficial effects would become less pro-
nounced over the course of the study) to the change
from baseline T12 (LI phase). We used the results of the
ANCOVAs (as previously described) as well as the quali-
tative comparison of ESs to compare the effects after the
LI phase vs. the full study period (LI+HI phase).
To examine ApoE4 as a potential moderator, we con-
ducted a repeated measures ANOVA with physical and
cognitive outcome variables as dependent variables, time
of measurement (baseline and T24) as a within-subject
factor, and group (exercise vs. control) and carrier
(ApoE4 carrier vs. non-carrier) as between-subject fac-
tors. We considered ApoE4 to moderate the effects of
exercise on physical or cognitive functions if there was a
significant three-way Group*Carrier*Time interaction.
Results
Figure 1 shows the flowchart of the study. Of the 916
persons that were screened for eligibility, 91 were ran-
domized (N = 46 exercise vs. N = 45 control; mean age =
82.3 ± 6.96; 59 women; a median level of education =
secondary lower education; mean MMSE = 20.2 ± 4.40;
use of walking aid N = 50). Of these 91 participants, 22
(24%) participants dropped out after allocation. There
were significantly more dropouts in the control (N = 15
(33%)) vs. exercise (N = 7 (15%)) intervention (χ2(1) =
4.08, p < 0.05). There were no differences with respect to
age, gender, level of education, and baseline MMSE be-
tween participants who dropped out vs. participants who
remained in the study (N = 69). Figure 1 shows the time
and reasons for dropout.
Intention-to-treat analyses
The current analyses involve the participants who per-
formed ≥ 5 assessments (N = 69; N = 39 exercise vs. N =
30 control; mean MMSE = 20.6 ± 4.38; 43 women).
Table 1 shows the baseline characteristics of this sample.
Additional file 1: Appendix 3 presents training charac-
teristics for the exercise (LI vs. HI phase) and control
groups. The overall attendance was ~ 60% for the exer-
cise group and ~ 70% for the control group. Attendance
was not significantly different for the walking vs.
strength sessions, LI vs. HI phase and exercise vs. con-
trol group. Participant satisfaction was generally high
but lowered for the HI vs. LI walking sessions. For the
HI vs. LI strength sessions, the RPE and number of repe-
titions were significantly higher with the added weight
being ~ 0.71 kg (there were no added weights in the LI
sessions). There was no loss of quality for the HI vs. LI
strength exercises. The contrast between LI and HI
walking was less pronounced. The total distance walked
in 30min was ~ 40m higher in the HI phase (1.30 km LI
vs. 1.34 km HI). However, the mean and maximum heart
rates were not significantly different between LI and HI
walking sessions. Furthermore, there were no significant
differences in the maximum heart rate between partici-
pants with and without beta blockers. Also, there were
no differences in the observer-rated RPE (for the LI
walking, HI walking, LI strength or HI strength sessions)
for participants with vs. without beta blockers (data not
shown). The mean HR of ~ 95 b/min−1 during LI and HI
walking sessions falls within the low to low-to-moderate
intensity range, and the maximum HR of ~ 135 b/min−1
during LI and HI walking sessions can be considered
high intensity according to ACSM guidelines [46] (given
the mean age = 81.8, HRmax = 208–0.7 × 81.8 = ~ 151).
The exercise intervention had a significant positive
effect on 6MWS after 18 (F(1, 66) = 5.12, p < 0.05) and 24
weeks (Table 2) (Fig. 2b), also after multiple testing
correction at 24 weeks (alpha-correction of 0.05/17 (17
functional measurements)). The ES increased from d =
0.04 at T12 to d = 0.41 at T24 (Table 2). At follow-up,
6MWS declined and was no longer significantly higher for
the exercise vs. control group (Fig. 2b) (Additional file 1:
Appendix 5). There were no significant effects of the exer-
cise vs. control intervention on the other physical mea-
sures (mean d = 0.18 for the LI phase and mean d = 0.13
for the HI phase; Table 2, Fig. 2c for leg strength).
There were no significant effects of the exercise vs.
control intervention on any of the cognitive measures
(mean d = − 0.03 for the LI phase and mean d = − 0.04
for the HI phase; Table 3, Fig. 2a for all STROOP
scores). Both the exercise and control participants
remained stable over the course of the study. There was
a significant effect on the STROOP interference quotient
in favor of controls after 12 weeks (Table 3), but this
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Fig. 1 CONSORT flowchart
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effect did not survive multiple testing correction (alpha-
correction of 0.05/17 (17 functional measurements)).
ApoE4 moderation
ApoE4 carriers (n = 30) were ~ 3 years younger than
non-carriers (n = 39) (non-significant difference) and
used more beta blockers (66.7% of carriers and 38.5% of
non-carries used beta blockers, χ2(1) = 5.40, p < 0.05).
There were no other significant baseline differences, also
with respect to the physical and cognitive function tests.
There were no significant three-way Time*Group*Car-
rier interactions for any of the cognitive or physical mea-
sures (all p > 0.05, Additional file 1: Appendix 4a-4c).
Discussion
Summary of results
This is the first assessor-blinded RCT investigating the
effects of LI vs. HI combined aerobic and strength exer-
cise in PwD. Gait speed significantly improved for the
exercise vs. control group after 24 weeks (d = 0.41, p <
0.05) but declined at follow-up. We found no significant
effects of exercise on the other physical functions. There
were no differences between the LI (mean d = 0.18) and
HI (mean d = 0.13) phase. There were no effects of exer-
cise on cognitive functions, and no differences between
the LI (mean d = − 0.03) and HI (mean d = − 0.04) phase.
ApoE4 carriership did not moderate the effects of exer-
cise on physical or cognitive function.
Feasibility of the exercise program
This exercise program was feasible in this sample of PwD.
The mean attendance rate was ~ 60% in the LI and HI
phase. All exercise participants were able to perform the
strength exercises with and without weights. There were
no serious study-related adverse events. Notwithstanding
the individual supervision, the mean attendance rate was
lower than what is considered necessary for functional im-
provements (i.e., ≥ 3 performed sessions per week) [41].
Low attendance rates were often caused by the unavail-
ability of the participant due to illness or scheduling con-
flicts. Furthermore, some participants were unwilling to
participate in all exercise sessions. The quality of the
strength exercises was rated ~ 2.5 on average which
amounts to a sufficient execution. Problems with the exe-
cution of exercises may arise due to poor physical fitness
and knee or hip complaints in PwD. Perhaps a higher
quality of execution would attribute to better exercise ef-
fects on functional outcomes. However, additional ana-
lyses (data not shown) did not show that higher
attendance or better quality was predictive of better phys-
ical or cognitive effects in PwD.
We aimed to contrast LI with HI exercise. Overall, our
results confirm the contrast between LI and HI exercise
(Additional file 1: Appendix 3). However, this contrast
was more pronounced for the LI vs. HI strength exercises
than for LI vs. HI walking. With respect to the strength
exercises, the average added weight of ~ 0.7 kg can be con-
sidered relevant given our participants’ poor physical fit-
ness. Furthermore, the number of repetitions was higher
in the HI vs. the LI strength sessions. With respect to
walking, the RPE was significantly higher in the HI phase
but the heart rate was not. With respect to the RPE, we
chose proxy report over self-report because our pilot data
(unpublished) showed that our participants had difficulties
in understanding the Borg scale. We chose to continu-
ously monitor the heart rate to have an objective measure
of exercise intensity. However, we are unsure if heart rate
is a reliable indicator of exercise intensity in PwD. All
types of dementia are associated with dysfunction of the
autonomic nervous system including heart rate variability
[61]. This may influence the heart rate response to exer-
cise in PwD. Future studies are needed to investigate
whether there are differences in heart rate response to ex-
ercise in PwD vs. healthy older adults.





Age (mean, SD) 81.7 (7.16) 82.1 (7.51)
Gender (N women, % total) 21 (53.8) 22 (73.3)†i
Level of education (N, % total)
1 = primary education only 10 (25.6) 8 (26.7)
2 = secondary lower education 25 (64.1) 19 (63.3)
3 = secondary higher education 4 (10.3) 3 (10.0)
Use of walking aid at baseline (N, % total) 17 (43.6) 19 (63.3)
Dementia diagnosis according to medical filea (N, % total)
1 = Alzheimer’s disease (AD) 14 (35.9) 7 (23.3)
2 = vascular dementia (VD) 3 (7.7) 1 (3.3)
3 =mixed (AD+VD) 3 (7.7) 5 (16.7)
4 = dementia with Lewy bodies (DLB) 0 (0.0) 1 (3.3)
5 = others/unspecifiedb 11 (28.2) 12 (40.0)
MMSEc (mean, SD) 21.4 (3.94) 19.5 (4.77)†j
APOEd genotype (N, % total)
Carrier (e3/e4 and e4/e4) 18 (46.2) 12 (40.0)
Non-carrier (e2/e2, e2/e3, e3/e3) 21 (53.8) 18 (60.0)
Number of medications usede (mean, SD) 5.2 (2.45) 5.1 (2.74)
Use of beta blockers (N, % total) 21 (53.8) 14 (46.7)
DBIf (mean, SD) 0.24 (0.38) 0.22 (0.31)
FCIg (mean, SD) 2.4 (1.66) 2.7 (1.96)
BMIh (mean, SD) 27.3 (3.53) 27.6 (3.71)
aN = 12 missing; bdiagnosis of “dementia” or “dementia syndrome”; cMini-
Mental State Examination; dapolipoprotein E, within the carrier group N = 2
homozygote in exercise group, N = 1 homozygote in the control group; eN = 1
missing; fDrug Burden Index, N = 4 missing; gFunctional Comorbidity Index,
N = 9 missing; hbody mass index. †Significant at p < 0.01. iχ (1) = 2.74, p = 0.098;
jF(1, 67) = 3.03, p = 0.086
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We had selective dropout in our sample as our base-
line sample (N = 91) showed no differences in baseline
characteristics (age, gender, education, MMSE, endur-
ance capacity, and use of walking aid; data not shown)
whereas in our analyzed sample (N = 69), exercise partic-
ipants had higher levels of physical and cognitive func-
tions at baseline compared with control participants.
Despite starting with LI exercise, lower functioning indi-
viduals were more likely to drop out of the exercise
group often within the first weeks of the study. This
could perhaps have been prevented with a more gradual
increase in session duration or frequency. Conversely,
higher functioning individuals were more likely to drop
out of the control group. This could perhaps have been
prevented with more challenging control activities or
better management of potential participants’ expecta-
tions for the control group. The higher dropout rate in
the control vs. exercise group may be due to lower par-
ticipant interest in the control vs. exercise group, per-
haps because control group activities (e.g., recreational
activities) were also offered at daycare facilities as part of
usual care.
Effects of exercise on physical function
Gait speed significantly improved with ~ 5% after 24
weeks. Gait speed is an important clinical measure in
older adults because it is associated with the rate of cogni-
tive decline [62], vulnerability to adverse events [63], and
survival [64]. The change in gait speed for participants in
the exercise group between baseline and T24 was ~ 0.05
m/s which is considered functionally meaningful [65]. Gait
speed may have been the most sensitive to changes con-
sidering the nature of our exercise program, in line with
the specificity principle (i.e., adaptations in gait speed are
more likely after a walking program compared to adap-
tions in balance or sit-to-stand measures) and previous
meta-analytic results that showed that gait speed was es-
pecially sensitive to progressive resistance training with
higher intensities [66]. It is unlikely that the effects of ex-
ercise on gait speed were random outliers as gait speed
improved in respectively 38% vs. 13% of exercise vs. con-
trol participants (change ≥ 0.05m/s). The finding that gait
speed improved more in the HI vs. the LI phase may be
indicative of a dose-response effect for intensity. The LI
vs. HI contrast was most pronounced for the strength ses-
sions. These results attest to a relationship between gait
speed improvements and strength improvements [67]. Al-
though there were no significant exercise effects on leg
strength, we deem a true lack of exercise effects on leg
strength unlikely given previous data [11, 14, 45]. There-
fore, we believe that a lack of significant (dose-response)
improvements in leg strength may have resulted from our
assessment method: PwD may be hesitant to generate
maximum force either in fear of pain or injury, or lack of
motivation. Also, PwD may have trouble comprehending
the test instructions. Exercise did not provide a protective
effect against gait speed losses when exercise was with-
drawn, as indicated by a decline in gait speed after detrain-
ing (at follow-up), although it should be noted that the
overall decline in gait speed from baseline to follow-up
was smaller in the exercise group (~ 0.04m/s) as com-
pared to the control group (~ 0.12m/s). The detrimental
effects of detraining on physical function are well known
in older persons with and without dementia [11, 68–70].
Thus, our results support the recommendation of con-
tinuous physical exercise for PwD.
Table 2 Descriptives, effect sizes, and results of ANCOVA for physical test scores
Testa Group Baseline 12 weeks 24 weeks Effect size,
baseline-12 weeksb
F(1, 66)c, p Effect size,
baseline-24 weeksb
F(1, 66)c, p
6MWT (m) Exercise 278 (89.4) 280 (87.0) 289 (95.0) 0.18 [− 0.30, 0.65] 2.73, p > 0.05 0.08 [− 0.40, 0.56] 1.36, p > 0.05
Control 234 (88.6) 222 (98.8) 238 (87.4)
SPPB (score) Exercise 8.75 (2.25) 9.19 (2.37) 8.96 (2.31) 0.28 [− 0.20, 0.76] 3.27c, p > 0.05 0.16 [− 0.32, 0.64] 2.46, p > 0.05
Control 7.77 (2.08) 7.58 (2.14) 7.61 (2.41)
6MWS (m/s) Exercise 0.93 (0.31) 0.93 (0.25) 0.98 (0.25) 0.04 [− 0.44, 0.52] 1.46, p > 0.05 0.41 [− 0.07, 0.90] 12.83, p < 0.001**
Control 0.85 (0.22) 0.84 (0.22) 0.79 (0.27)
FICSIT-4 (score) Exercise 3.36 (1.06) 3.45 (1.19) 3.30 (1.31) 0.15 [− 0.33, 0.63] 1.45, p > 0.05 − 0.15 [0.63, 0.33] 0.09, p > 0.05
Control 2.90 (1.40) 2.81 (1.24) 3.03 (1.35)
TUG (s) Exercise 14.4 (6.24) 13.6 (5.56) 14.1 (6.62) 0.23 [− 0.26, 0.71] 2.35, p > 0.05 0.17 [− 0.31, 0.66] 1.43, p > 0.05
Control 17.3 (5.56) 17.8 (7.57) 18.0 (7.20)
Leg strength (N) Exercise 202 (91.4) 208 (98.4) 214 (95.8) 0.21 [− 0.27, 0.69] 2.01, p > 0.05 0.07 [− 0.41, 0.55] 0.39, p > 0.05
Control 188 (51.4) 177 (58.5) 194 (67.0)
Values are mean (SD). N total = 69; N = 39 exercise vs. N = 30 control. Baseline-12 weeks is the low-intensity phase; baseline-24 weeks is the full study period (low-
intensity and high-intensity phase). a6MWT 6-meter walk test, SPPB short physical performance Battery, 6MWS 6-meter walk speed; TUG Timed Up & Go. bCohen’s
d with 95% CI, positive effect sizes are in favor of exercise group. cANCOVA with baseline as a covariate and use of walking aid as a factor, the main effect of
group (exercise vs. control). **Significant at p < 0.001
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Although we selected intervention characteristics (i.e.,
combined walking and strength exercise, 3 sessions/week
for 24 weeks) that previously showed the highest efficacy
on physical outcomes in PwD [11, 45], we found no sig-
nificant effects of exercise on physical function. This was
contrary to other successful interventions that showed
combined exercise to be related to better endurance,
mobility, muscle strength, and balance in PwD [11, 45,
70, 71]. Unfortunately, a previous systematic review on
the effects of exercise on physical function in PwD could
not yet determine the characteristics of successful
interventions [45]. Although a larger training volume in
general was related to more improvements in physical
function, there is currently not enough evidence to de-
termine how program duration, session duration, fre-
quency, and intensity each contribute to exercise effects
on functional outcomes in PwD [5]. Partly, this results
from a scarcity of studies that report dose parameters
subjectively and/or objectively [5], and a shortage of
studies in PwD in which the effects of different exercise
doses are compared among randomized subjects or con-
ditions [5], further illustrating the need for the current
Fig. 2 Scores on STROOP, 6-meter walking speed and leg strength for the intervention vs. control group
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study. Last, the generally low number of participants
(mean N = 56) across the aforementioned exercise stud-
ies [11, 45, 70, 71] may complicate the interpretation of
exercise effects on physical function in PwD. Several
other factors may have weakened the exercise effects in
our study. First, exercise interventions specifically in
daycare or residential care settings have generated con-
flicting results [72–75]. Perhaps, exercise effects are
lower for PwD in daycare or residential care due to
stressors related to disease progression, disease aware-
ness, caregiver burden, and irregularity of daily life. Fu-
ture studies could consider the impact of the living
environment on the effects of exercise in PwD. Further-
more, physical function levels of our control group
remained stable over the course of the study, which
could attest to a confounding effect of daycare or resi-
dential care activities. However, this is unlikely as we
found a drop in the level of physical activity after the
intervention (additional measurements using structured
questionnaires with formal and informal caregivers, data
not shown). Perhaps, the cognitive stimulation of the
control activities afforded physical function benefits
which strengthens the evidence for reverse causality in
the relationship between physical and cognitive func-
tions that were previously found for gait speed [76]. Fur-
thermore, the flexibility exercises of the control group
require coordination which may have afforded cognitive
benefits.
Effects of exercise on cognitive function
We found no effects of exercise vs. control activities on
cognitive function and no differences between LI (d = −
0.03) and HI (d = − 0.04) exercises. Earlier evidence for
the effects of exercise on cognition is conflicted for PwD
in nursing homes [10, 11, 13, 71, 77] as well as commu-
nity settings [14, 78–81]. Studies specifically in daycare
or residential care settings are scarce. One RCT in PwD
attending daycare showed that aerobic training had fa-
vorable effects on psychomotor speed only [82].
Altogether, there is a lack of convincing evidence for the
efficacy of exercise for cognition in PwD. Shared study
characteristics of ten exercise interventions that showed
Table 3 Descriptives, effect sizes, and results of ANCOVA for cognitive test scores






F(1, 66)d, p Effect sizeb,
baseline-24 weeks
F(1, 66)d, p
MMSE (score) Exercise 21.4 (3.94) 21.0 (4.38) 20.4 (4.77) − 0.05 [− 0.53, 0.43] 0.11, p > 0.05 − 0.04 [− 0.52, 0.44] 0.04, p > 0.05
Control 19.5 (4.77) 19.4 (5.64) 18.8 (5.88)
TMTA (s) Exercise 121 (64.2) 123 (63.7) 126 (65.3) − 0.03 [− 0.51, 0.45] 0.51, p > 0.05 − 0.14 [− 0.62, 0.34] 0.52, p > 0.05
Control 156 (65.2) 156 (61.1) 153 (56.6)
STROOP word
(no. of correct responses)
Exercise 54.3 (21.1) 55.3 (19.7) 53.5 (20.3) 0.07 [− 0.41, 0.55] 0.64, p > 0.05 0.13 [− 0.35, 0.61] 1.35, p > 0.05
Control 50.9 (22.5) 50.5 (22.0) 47.4 (20.1)
STROOP color
(no. of correct responses)
Exercise 41.3 (14.8) 43.9 (17.0) 43.3 (16.3) 0.17 [− 0.31, 0.65] 1.93, p > 0.05 0.03 [− 0.45, 0.51] 0.47, p > 0.05
Control 36.4 (17.6) 36.3 (18.0) 38.0 (15.4)
STROOP color-word
(no. of correct responses)
Exercise 17.6 (10.4) 16.5 (10.8) 17.2 (10.7) − 0.24 [− 0.72, 0.24] 0.45, p > 0.05 − 0.37 [− 0.85, 0.12] 0.61, p > 0.05
Control 13.5 (9.05) 14.9 (8.63) 16.8 (8.83)
STROOP interference quotient Exercise 3.46 (3.18) 4.04 (3.68) 3.56 (2.81) − 0.49 [− 0.98, 0.00] 4.29, p =
0.04*
− 0.42 [− 0.90, 0.07] 2.13, p > 0.05
Control 4.19 (3.99) 3.14 (2.21) 3.00 (2.21)
DSFW (no. of correct responses) Exercise 6.79 (1.77) 7.11 (2.14) 6.67 (1.80) 0.15 [− 0.33, 0.63] 0.96, p > 0.05 − 0.13 [− 0.61, 0.35] 0.40, p > 0.05
Control 6.53 (1.55) 6.58 (1.67) 6.64 (1.91)
DSBW (no. of correct responses) Exercise 4.00 (1.39) 4.00 (1.54) 4.01 (1.31) − 0.03 [− 0.51, 0.45] 0.20, p > 0.05 0.10 [− 0.38, 0.58] 0.15, p > 0.05
Control 4.17 (1.32) 4.21 (1.48) 4.04 (1.60)
VMSFW (no. of correct
responses)
Exercise 5.78 (1.95) 5.50 (1.57) 5.23 (1.50) 0.04 [− 0.43, 0.52] 2.01, p > 0.05 − 0.05 [− 0.53, 0.43] 1.20, p > 0.05
Control 4.96 (1.80) 4.60 (1.82) 4.50 (2.05)
VMSBW (no. of correct
responses)
Exercise 4.31 (2.05) 4.23 (1.93) 4.56 (1.71) 0.14 [− 0.34, 0.62] 0.71, p > 0.05 0.33 [− 0.16, 0.81] 2.92, p > 0.05
Control 4.30 (1.86) 3.94 (1.94) 3.93 (1.98)
Fluency
(no. of correct responses)
Exercise 18.9 (7.73) 18.3 (8.27) 21.6 (8.49) − 0.06 [− 0.54, 0.42] 0.03, p > 0.05 0.13 [− 0.35, 0.61] 2.00, p > 0.05
Control 14.7 (9.39) 14.6 (9.95) 16.3 (9.52)
Values are mean (SD). N total = 69; N = 39 exercise vs. N = 30 control. Baseline-12 weeks is the low-intensity phase; baseline-24 weeks is the full study period (low-
intensity and high-intensity phase). aMMSE Mini-Mental State Examination, TMTA Trail Making Test A, DSFW Digit Span Forward, DSBW Digit Span Backward,
VMSFW Visual Memory Span Forward, VMSBW Visual Memory Span Backward, Fluency phonemic fluency test. bCohen’s d with 95% CI, positive effect sizes are in
favor of exercise group. dANCOVA with baseline as a covariate, the main effect of group (exercise vs. control). *Significant at p < 0.05
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positive effects on cognitive function in PwD [11, 71, 78,
81, 83–88] are a low number of participants (N ~ 30 for 9
interventions); lower baseline MMSE scores (MMSE indi-
cative of low-to-moderate dementia for 6 interventions);
institutionalized setting (7 interventions performed in NH
PwD); program duration between 9 and 24weeks (9 inter-
ventions); multimodal intervention consisting of aerobic
training (7 interventions) with added strength, balance, or
cognitive training (5 interventions); and high-to-excellent
participant attendance and a non-active control group (9
interventions). However, it should be noted that studies
with low N effect sizes may be overestimated [89]. Fur-
thermore, a previous systematic review in PwD found the
reliability of six motor tests for endurance, gait speed,
balance, strength, and functional mobility to be good-to-
excellent in PwD [90], but the reliability was lower for
lower-functioning individuals. Also, dementia-related fluc-
tuations in cognitive function may lower the reliability of
cognitive tests in general. Thus, the potential lower reli-
ability of assessments in PwD warrants caution in inter-
preting the abovementioned and current exercise effects.
As mentioned previously for physical function, other fac-
tors may weaken the exercise effects on cognitive function.
Dementia-related factors such as disease progression, en-
vironmental factors, and caregiver burden may weaken
the effects of exercise on cognition in PwD. Alternatively,
a lack of convincing effects of exercise on cognition may
indicate that exercise alone does not sufficiently stimulate
cognition in PwD. Diversity in symptoms and disease eti-
ology may require diverse interventions, and exercise
could be one option for PwD in addition to cognitive
training, social stimulation, and sensory enrichment, pref-
erably as part of a multicomponent program [91, 92]. Re-
cent conceptual models suggest that it may be necessary
to perform cognitive and motor tasks in combination and
concurrently to increase the efficacy of exercise interven-
tions [93]. The optimal duration for such a multicompo-
nent program is yet to be determined by future studies. In
addition to a multicomponent program, a more individu-
alized approach as opposed to a standardized program
may be necessary for optimal results [94]. Contrary to the
clinical expectations, both the exercise and control partici-
pants remained stable over 24 weeks which attests to the
beneficial effects of attention and control activities on cog-
nition. Controls participated in recreational activities
which may stimulate aspects of cognition in PwD [95]. In-
deed, the average MMSE decline of − 0.7 in the control
group (Table 3) is lower than the ~ 1.2–4 point decline
that was previously found in comparable samples of PwD
[80, 96]. To conclude, for PwD, performing activities of
any kind may be beneficial for cognition.
Contrary to our expectations, there were no differen-
tial effects of the LI and HI phases. We expected a dose-
response relationship for intensity between exercise and
cognition because higher intensity exercise is related to
better fitness parameters [44] which could translate to
changes in cognitive function. In a previous meta-
analysis, we could not relate exercise intensity to
changes in cognitive function in older adults with cogni-
tive impairments [5], but studies that compared exercise
intensities among randomized subjects were lacking.
This is the first such study in patients with dementia.
With this study, we cannot provide evidence that the
effects of exercise on cognition can be enhanced by in-
creasing exercise intensity. It should be noted that the
distinction LI-HI could be made for strength training,
but not convincing for walking. Future studies could in-
vestigate whether exercise intensity is related to changes
in physiological parameters that may underlie cognitive
changes in patients with dementia.
ApoE4 moderation
We found no significant three-way Group*Time*Carrier
interactions for any of the physical or cognitive mea-
sures. However, there was a trend for improved MMSE
scores for non-carriers in the exercise group and de-
creased for all other groups (F(1,65) = 3.28, p = 0.075,
Additional file 1: Appendix 4d). This finding comple-
ments post hoc findings from the FAB study that
showed a significantly better change in global cognition
(ADAS-COG) in ApoE4 non-carriers in the exercise
group compared to others [97]. A higher rate of clinical
decline and atrophy in ApoE4 carriers vs. non-carriers
[98] may negate the beneficial effects of physical activity.
However, we urge caution when interpreting this result
as we found it for one test only, and it was not signifi-
cant. Thus, at this time, we cannot conclude that ApoE4
carriership is an important moderator in exercise studies
with PwD.
Strengths and limitations
There were several strengths to this study. Our design
allowed us to investigate the differential effects of LI and
HI exercise, and we carefully monitored exercise inten-
sity both objectively and subjectively. As compared to a
three-group design with LI exercise vs. HI exercise vs.
control, our current two-group exercise vs. control de-
sign ensured that participants could gradually build up
exercise intensity and heterogeneity remained as low as
possible. Furthermore, we conducted our study in a
practical health care setting to strengthen the ecological
validity of our findings. Last, we opted for individually
supervised sessions in a carefully controlled design.
Several limitations warrant caution in the interpret-
ation of our results. The current results have to be inter-
preted in light of the limited sample size, further
reduced by dropouts. In addition, the large heterogeneity
in dementia diagnoses and the large number of
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unspecified diagnoses may have inflated variation,
thereby reducing the power of the current study. Also,
in our study, we determined the exercise intensity using
the RPE and HRmax as complementary measures, in
addition to other variables including progression and
variation in exercises, in accordance with the suggestions
for determining the dosage of exercise [99]. These
methods are not without limitations. HRmax is highly
variable in old adults [100] which warrants caution in
applying measures of HRmax in exercise studies with
old adults. However, we chose to predict HRmax using
age as we doubt the feasibility of exercise stress testing
in PwD. Subjectively, intensity was determined through
observer-rated RPE using a Borg scale, but the Borg
scale is not validated in PwD. Furthermore, there may be
discrepancies between HRmax and RPE, potentially
influenced by beta blocker use or other intrapersonal
characteristics. In our study, we instructed the research
assistants to rely upon RPE in case of discrepancies.
However, this method may have led to some participants
being slowed down or stimulated to a larger extent than
what was targeted. Furthermore, we expected that po-
tential beneficial exercise effects would become less pro-
nounced over the course of the study, but the current
design (12 weeks LI vs. 12 weeks HI exercise) does not
allow for confirmation of this expectation. Furthermore,
the study was set in fall/winter for logistical reasons, and
we cannot rule out seasonal influences on dementia de-
cline. Unfortunately, we have no information on the
neurobiological factors (i.e., changes in IGF-1, VEGF,
BDNF levels) hypothesized to underlie the beneficial ef-
fect of exercise on brain health. Such information is im-
portant because Alzheimer’s disease (AD) has been
associated with lower serum levels of IGF-1 [101] and
BDNF [102]. Although lower levels in these neurobio-
logical factors could leave more room for improvement,
it is also possible that the neurobiological system is less
responsive in PwD [103, 104]. It is left to future exercise
studies to account for changes in such neurobiological
factors in PwD. Last, the cognitive tests that we
employed are often used but not all psychometrically
evaluated in PwD [50], and dementia-related fluctuations
in cognitive function may lower the reliability of cogni-
tive tests in general. Future studies are needed to valid-
ate commonly used neuropsychological tests and adapt
tests to suit the needs of PwD.
Conclusions
Exercise was superior to control activities for better gait
speed. This is an important result because gait speed has
high clinical relevance in older adults. There was a dose-
response relationship for the intensity between exercise
and gait speed improvements, which may have been
fueled by strength improvements in the HI phase. We
found no significant effects of exercise on the other
physical functions. Exercise was not superior to control
activities for cognition in PwD. With gait speed as an ex-
ception, we found no evidence that higher intensity ex-
ercise afforded more physical or cognitive benefits.
Altogether, our results are not in contrast with the rec-
ommendation for physical activity over control activities
for PwD, preferably at higher intensities, in accordance
with ACSM’s guidelines [46]. The current results should
be carefully interpreted in light of the limited sample
size (N = 91 PwD included with N = 118 inclusions ne-
cessary for sufficient power), further reduced by selective
dropout. Although our overall dropout rate of 24% was
as expected, selective dropout in particular may be pre-
vented in future studies with a more gradual increase in
exercise session duration or frequency (for lower-
functioning PwD in an exercise group) or more challen-
ging control activities (for higher-functioning PwD in a
control group). With an eye on future studies, diversity
in dementia symptoms and etiology may require diverse
interventions and future studies are needed to investi-
gate whether multicomponent programs including but
not limited to physical exercise, cognitive training, social
stimulation, and sensory enrichment are indeed more ef-
fective for physical and cognitive function in PwD. In
addition to multicomponent programs, a more individu-
alized approach as opposed to standardized programs
may be necessary for optimal results. For personalization
of treatments, we advise future researchers to collect
data on the characteristics of responders and non-
responders to lifestyle programs including, but not lim-
ited to, physical exercise.
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